Xenetic Biosciences Announces Dosing Of First Patient On Dialysis In Phase 2a Clinical Study Of Erepoxen®
6/11/2014 7:13:52 AM
LEXINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that its partner, the Serum Institute of India, has dosed the first patient in the second cohort of a Phase 2a clinical, sequential single dose study of intravenously (IV) administered ErepoXen® (PSA EPO) for the treatment of anemia in Chronic Kidney Disease (CKD) patients on dialysis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by